Therapeutics, Inc. announces it has formed a Scientific Advisory Board (SAB) in support of the development of its lead therapeutic candidate QN-302 for the potential treatment of pancreatic cancer and other G4-prevalent solid tumors. Members of the QN-302 Scientific Advisory Board include: Patricia LoRusso, D.O., Professor of Medicine, Medical Oncology and Associate Cancer Center Director, Experimental Therapeutics, Yale School of MedicineDr. LoRusso brings more than 25 years of expertise in medical oncology, drug development, and early phase clinical trials. Prior to her Yale appointment as Professor of Medicine (Medical Oncology), she served in numerous leadership roles at Wayne State University'sBarbara Karmanos Cancer Institute, most recently as director of the Phase I Clinical Trials Program and of the Eisenberg Center for Experimental Therapeutics.

Dr. LoRusso is the recipient of numerous prestigious awards including most recently, the Joseph H. Burchenal Award for Outstanding Achievement in Clinical Cancer Research presented to her by the American Association for Cancer Research inApril 2022. Dr. LoRusso has also been involved in many service disciplines at the National Cancer Institute. She has served on the Investigational Drug Steering Committee (IDSC) since inception (2005-present) and served as its chair from 2011-2013.

She was a member of the steering committee that convened after the Blue-Ribbon Panel to execute on their recommendations. She served a 4-year term (2015-2019) on the Board of Scientific Council (BSC), reviewing the intramural programs for quality, content, productivity, and funding. Dr. LoRusso has served in leadership positions of several other organizations.

She has served on the Board of Directors and numerous scientific and education committees of the American Association for Cancer Research (AACR), the education and scientific committees of the American Society of Clinical Oncology (ASCO), and the steering committee for the Food and Drug Administration (FDA) Accelerating Anticancer Agent Development and Validation Workshop, as examples.Lillian Siu, M.D., Senior Scientist, Princess Margaret Cancer Centre, Toronto, Ontario, Canada, and Professor of Medicine, University of Toronto Dr. Lillian Siu is a senior medical oncologist at Princess Margaret Cancer Centre and a Professor of Medicine at the University of Toronto. She directs the Phase I Program and is the clinical leader for the Tumor Immunotherapy Program at the Princess Margaret Cancer Centre. She holds the BMO (Bank of Montreal) hair in Precision Genomics (2016-2026).

Dr. Siu is the Co-Contact Principal Investigator of the North American Star Consortium UM1 Phase I Grant as part of the U.S. National Cancer Institute Experimental Therapeutics Clinical Trials Network. Dr. Siu has served on the Board of Directors for both ASCO and AACR.Dr. Siu was the recipient of the U.S. National Cancer Institute Michaele C. Christian Award in Oncology Drug Development in 2010; and also the recipient of the 2022 ESMO Targeted Anticancer Therapies Honorary Award. Dr. Siu is the inaugural co-editor-in-chief of AACR's new journal Cancer Research Communications.

She is also on the Editorial Boards for Cell and Cancer Cell. Michael Gordon, M.D., Chief Medical Officer, HonorHealth Research Institute, Scottsdale, Ariz. and Clinical Professor of Medicine, University of Arizona College of Medicine.Dr. Gordon is a medical oncologist with a special interest in sarcoma and phase I investigational drug development.

His career has focused on translational cancer therapy trials, and he has led efforts in cutaneous oncology both at Indiana University as well as at the HonorHealth Research Institute, which is currently focused on the Arizona Rare Cancer Initiative. The organization is investing significant effort in the strategy for developing treatments for uveal melanoma and rare sarcomas including translational studies as well as pre-clinical models.Dr. Gordon is the former President and CEO of Pinnacle Oncology Hematology in Scottsdale, AZ, and is currently Chief Medical Officer at the HonorHealth Research Institute in Scottsdale, AZ, Clinical Professor of Medicine at the University of Arizona College of Medicine in Phoenix and Clinical Professor at the Translational Genomics Research Institute in Phoenix. Dr Gordon was instrumental in the clinical development of antiangiogenic agents for the treatment of cancer and more recently, led the effort for the development of new immuno-oncology (I-O) therapies to treat cancer.

Anthony Tolcher, M.D., Co-Founder, START and NEXT Oncology, San Antonio, Tex. Dr. Anthony Tolcher is a medical oncologist and co-founder of START and NEXT Oncology, both world-class clinical oncology sites dedicated to Phase 1 clinical trials in oncology. He is dedicated to the development of new anticancer agents -- including clinical trials and therapies -- for patients looking for their next option now that their current cancer therapy is no longer working to their benefit.Dr. Tolcher was a Fogarty Fellow at the National Institute of Health and received the Murray Muirhead Award for humanitarian and academic excellence and the Goel Prize in Medicine for excellence in the Clinical Disciplines.

He is a Fellow of the Royal College of Physicians of Canada; a Diplomate of the American Board of Internal Medicine and Medical Oncology; and a member of the American College of Physicians, and the American Society of Clinical Oncologists. He also serves as a member of the American Society of Clinical Oncology Scientific Program Committee and the Cancer Education Committee. Christopher Slapak, M.D., Adjunct Clinical Associate Professor of Medicine, Indiana University School of Medicine and Pharmacology.